Trials / Completed
CompletedNCT06381986
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
A Clinical Study on the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution in the Treatment of Corneal Erosion in Patients With Sjogren's Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Sunhawk Vision Biotech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients. SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Detailed description
Participants will be randomized to treatment with SHJ002 Ophthalmic Solution or vehicle which will be administered to each eye twice daily for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHJ002 | Topical ophthalmic |
| OTHER | Vehicle | Topical ophthalmic |
Timeline
- Start date
- 2024-06-28
- Primary completion
- 2025-04-10
- Completion
- 2025-04-17
- First posted
- 2024-04-24
- Last updated
- 2025-08-22
- Results posted
- 2025-08-22
Locations
6 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06381986. Inclusion in this directory is not an endorsement.